Nvidia demand continues to outweigh supply, JPMorgan says
Director Paul B. Manning of Liquidia Corp (NASDAQ:LQDA) sold a total of 671,837 shares of common stock between August 28 and September 2, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The sales amounted to approximately $18.9 million, with prices ranging from $27.62 to $29.14. The transactions occurred as the stock trades near its 52-week high of $29.28, having delivered an impressive 200% return over the past year. InvestingPro data indicates the stock is currently in overbought territory.
On August 28, Manning sold 154,337 shares at a weighted average price of $27.94, for a total value of $4,312,675.78. The next day, August 29, he sold 188,232 shares at a weighted average price of $27.62, for a total value of $5,209,987.84. On September 2, Manning executed two separate sales: 254,038 shares at a weighted average price of $28.67, for a total value of $7,271,449.46 and 74,230 shares at a weighted average price of $29.14, for a total value of $2,162,062.20.
Following these transactions, Manning continues to hold shares of Liquidia Corp both directly and indirectly through various entities.
In other recent news, Liquidia Technologies reported its second-quarter 2025 earnings, highlighting a substantial revenue increase. The company achieved $8.8 million in revenue, significantly exceeding the forecast of $3.92 million, primarily driven by robust sales of its Yutrepia product. Despite a larger-than-expected loss per share of $0.49 compared to the forecasted $0.42, the market responded positively. Following these results, several analysts adjusted their outlooks on Liquidia. Raymond James raised its price target to $41, maintaining a Strong Buy rating, citing a positive outlook for Yutrepia’s launch. BTIG also increased its price target to $49, noting stronger-than-expected patient adoption. Wells Fargo raised its price target to $31, highlighting the product launch’s performance that surpassed expectations. Additionally, Jefferies initiated coverage with a Buy rating and a $43 price target, following the FDA approval of Yutrepia for pulmonary conditions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.